# EDGAR Filing Document

**Accession Number:** 0001351172
**File Stem:** 0000950170-23-011407
**Filing Date:** 2023-3
**Character Count:** 4528
**Document Hash:** a066a1ee7e6ca825c9cd058c7c29e7b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-011407.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0000950170-23-011407

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230331

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminal BioSciences Inc.
- **CENTRAL INDEX KEY:** 0001351172
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39131
- **FILM NUMBER:** 23788158

**BUSINESS ADDRESS:**
- **STREET 1:** 231 DUNDAS STREET EAST
- **CITY:** BELLEVILLE
- **STATE:** A6
- **ZIP:** K8N 1E2
- **BUSINESS PHONE:** 450-781-0115

**MAIL ADDRESS:**
- **STREET 1:** 440 ARMAND-FRAPPIER BLVD.
- **STREET 2:** SUITE 300
- **CITY:** LAVAL
- **STATE:** A8
- **ZIP:** H7V 4B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProMetic Life Sciences Inc
- **DATE OF NAME CHANGE:** 20060126

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of March 2023**

**Commission File Number: 001-39131**

**LIMINAL BIOSCIENCES INC.**

**(Translation of registrant's name into English)**

------

**440 Armand-Frappier Boulevard, Suite 300**

**Laval, Québec**

**H7V 4B4**

**(Address of principal executive office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 Form 20-F  Form 40-F

------

**<u>INCORPORATION BY REFERENCE</u>**

This Report on Form 6-K (the "Report") and Exhibit 99.1 to this Report are hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

On March 31, 2023, Liminal BioSciences Inc. filed a Notice of Meeting and Record Date in preparation for its annual general meeting of security holders. Shareholders can visit the investor website to access a copy of the annual report on Form 20-F here: https://investors.liminalbiosciences.com

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [<u>Notice of Meeting and Record Date</u>](lmnl-ex99_1.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** |
| Date: March 31, 2023 | By: | /s/ Bruce Pritchard | /s/ Bruce Pritchard |
|  |  | Name | Bruce Pritchard |
|  |  | Title: | Chief Executive Officer |

---

------

## Ex-99

<br>**Exhibit 99.1**

![img164290822_0.jpg](img164290822_0.jpg)<br>1500 Robert-Bourassa Blvd., 7th Floor<br>Montreal QC, H3A 3S8<br>www.computershare.com

<br>March 31, 2023<br>To: All Canadian Securities Regulatory Authorities<br>

**Subject: LIMINAL BIOSCIENCES INC**<br>Dear Sir/Madam: <br>We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:<br>Meeting Type : Annual General Meeting<br>Record Date for Notice of Meeting : April 26, 2023<br>Record Date for Voting (if applicable) : April 26, 2023<br>Beneficial Ownership Determination Date : April 26, 2023<br>Meeting Date : June 5, 2023<br>Meeting Location (if available) : Virtual Meeting<br>Issuer sending proxy related materials directly to NOBO: No<br>Issuer paying for delivery to OBO: Yes<br>**Notice and Access (NAA) Requirements:**<br>NAA for Beneficial Holders Yes<br>Beneficial Holders Stratification Criteria: Not Applicable<br>NAA for Registered Holders Yes<br>Registered Holders Stratification Criteria: Not Applicable<br>

------

**Voting Security Details:<br>Description CUSIP Number ISIN**<br>COMMON SHARES 53272L202 CA53272L2021<br>Sincerely, <br>**Computershare**<br>Agent for LIMINAL BIOSCIENCES INC

------